Abstract: Provided are methods for treating tumors and/or cancers in subjects in need thereof. In some embodiments, the method include administering to the subject an inhibitor of a Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) 5 biological activity and/or a checkpoint inhibitor. In some embodiments, the cancer is a solid tumor. Also provided are compositions that have an effective amount of an inhibitor of a Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) biological activity and/or an effective amount of a checkpoint inhibitor; and an effective amount of a DR5 agonist, which can be a bispecific antibody; bispecific antibodies that has a first antigen binding site that is specific for the DRS polypeptide and a second antigen binding site that is specific for the ROCK1 polypeptide, the CTLA4 polypeptide, the PD-1 polypeptide, or the PD-L1 polypeptide; compositions for use in treating tumors and/or cancers, including bispecific antibodies.

Abstract: Methods for sensitizing tumors and/or cancers in subjects to therapeutic agents are provided. In some embodiments, the methods include administering to the subject one or more compositions that include an effective amount of an inhibitor of TRIM37 activity. Also provided are methods for sensitizing tumors and/or cancers in subjects to therapeutic agents by administering to the subjects one or more compositions that include an effective amount of an inhibitor of TRIM37 activity and purified and isolated antibodies and fragments thereof that have at least one paratope and further have a linker sequence through which the antibody can be conjugated to a carrier in which the linker sequence includes the amino acid sequence ((X)3Cys(X)3, wherein each X is independently any amino acid.

Abstract: The present disclosure relates to targeting of miRNA to activate expression of genes on the inactivated X chromosome. This gene therapy is useful for treating X-linked disorders, including Rett syndrome.

Abstract: Therapeutic antibodies targeting ovarian cancer (OvCa)-enriched receptors have largely been disappointing due to limited tumor specific antibody-dependent cellular cytotoxicity (ADCC). Disclosed herein is a symbiotic approach that is highly selective and superior compared to investigational clinical antibodies. This Bispecific-Anchored Cytotoxicity-Activator (BaCa) antibody is rationally designed to instigate “cis” and “trans” cytotoxicity by combining specificities against folate receptor alpha-1 (FOLR1) and death receptor 5 (DR5). Whereas the in vivo agonist DR5 signaling requires Fc?RIIB interaction, the FOLR1 anchor functions as a primary clustering point to retain and maintain a high-level of tumor-specific apoptosis. Disclosed herein are studies that strategically make use of a tumor-cell enriched anchor receptor for agonist death-receptor targeting to generate a clinically viable strategy for OvCa.